Inclusion Criteria:

- Histologic or cytologic diagnosis of urothelial (transitional cell) carcinoma with
the exception of micropapillary subtype

- Patients must have recurrent disease (locally advanced or metastatic) that is not
amenable to local therapy or newly diagnosed distant metastatic disease

- Measurable disease defined by RECIST v.1.0

- ECOG performance status of 2 or better

- Adequate organ and bone marrow function defined as

Exclusion Criteria:

- Other tumor type than urothelial carcinoma

- Presence or history of CNS metastasis

- Prior systemic chemotherapy or immunotherapy (but prior local intravesical
chemotherapy or immunotherapy was allowed. And recurrent disease after adjuvant or
neoadjuvant cisplatin-based systemic chemotherapy is allowed if the last chemotherapy
was administered 1 year or more before the patient enrollment.)

- Presence of second primary malignancy (except in situ carcinoma of the cervix or
adequately treated basal cell carcinoma of the skin)

- Peripheral sensory neuropathy grade 2 or worse

- Other serious illness or medical conditions